tiprankstipranks
Top Stocks
U.S. Stock Market OverviewTop Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
Top ETFs by AUMSPY ETFQQQ ETF
Stock Comparison
Energy StocksOil StocksBest Value StocksAirline StocksElectric Vehicle StocksMATANA Stocks
New
Bank StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
Global Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Top ETFs by AUM
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
U.S. Markets
Market Movers
Expert Center
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
Top ETFs by AUM
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Energy Stocks
EV Stocks
Crypto News
Dividend Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

ALLO Stock Latest News

Allogene Therapeutics presents preclinical Dagger platform technology data
The FlyAllogene Therapeutics presents preclinical Dagger platform technology data
7d ago
ALLO
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
Press ReleasesAllogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
7d ago
ALLO
Allogene announces publication of preclinical study on DLL3, AlloCAR T
The FlyAllogene announces publication of preclinical study on DLL3, AlloCAR T
15d ago
ALLO
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Press ReleasesAllogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
15d ago
ALLO
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
Press ReleasesAllogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
16d ago
ALLO
Allogene Therapeutics announces publication of Phase 1 UNIVERSAL study data
The FlyAllogene Therapeutics announces publication of Phase 1 UNIVERSAL study data
16d ago
ALLO
Allogene Therapeutics upgraded to Overweight from Neutral at JPMorgan
The FlyAllogene Therapeutics upgraded to Overweight from Neutral at JPMorgan
16d ago
ALLO
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Press ReleasesAllogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
22d ago
ALLO
Baird upgrades ‘differentiated story’ Allogene Therapeutics to Outperform
The FlyBaird upgrades ‘differentiated story’ Allogene Therapeutics to Outperform
1M ago
ALLO
Allogene Therapeutics upgraded to Outperform from Neutral at Baird
The FlyAllogene Therapeutics upgraded to Outperform from Neutral at Baird
1M ago
ALLO
Allogene Therapeutics initiated with a Buy at EF Hutton
The FlyAllogene Therapeutics initiated with a Buy at EF Hutton
1M ago
ALLO
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Press ReleasesAllogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1M ago
ALLO
Zai Lab appoinst Amado as President, Head of Global Oncology R&D
The FlyZai Lab appoinst Amado as President, Head of Global Oncology R&D
1M ago
ALLO
ZLAB
Allogene Therapeutics appoints Zachary Roberts as EVP, research and development
The FlyAllogene Therapeutics appoints Zachary Roberts as EVP, research and development
1M ago
ALLO
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
Press ReleasesAllogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
1M ago
ALLO
Cantor biotech/biopharma analysts hold an analyst/industry conference call
The FlyCantor biotech/biopharma analysts hold an analyst/industry conference call
2M ago
BMY
JNJ
Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
The FlyAllogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
2M ago
ALLO
Allogene Therapeutics downgraded to Underperform from Buy at BofA
The FlyAllogene Therapeutics downgraded to Underperform from Buy at BofA
2M ago
ALLO
Cantor biotech/biopharma analysts hold an analyst/industry conference call
The FlyCantor biotech/biopharma analysts hold an analyst/industry conference call
2M ago
BMY
JNJ
Oppenheimer emerging biotech analysts to hold analyst/industry conference call
The FlyOppenheimer emerging biotech analysts to hold analyst/industry conference call
2M ago
BMY
ACET
Oppenheimer emerging biotech analysts to hold analyst/industry conference call
The FlyOppenheimer emerging biotech analysts to hold analyst/industry conference call
2M ago
BMY
ACET
Allogene unveils Dagger technology during R&D showcase
The FlyAllogene unveils Dagger technology during R&D showcase
2M ago
ALLO
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
Press ReleasesAllogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
2M ago
ALLO
Allogene Therapeutics to hold a research and development showcase
The FlyAllogene Therapeutics to hold a research and development showcase
2M ago
ALLO
Allogene Therapeutics to hold a research and development showcase
The FlyAllogene Therapeutics to hold a research and development showcase
2M ago
ALLO
Allogene Therapeutics to hold a research and development showcase
The FlyAllogene Therapeutics to hold a research and development showcase
2M ago
ALLO
Oppenheimer emerging biotech analysts to hold analyst/industry conference call
The FlyOppenheimer emerging biotech analysts to hold analyst/industry conference call
2M ago
BMY
ACET
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
Press ReleasesAllogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
3M ago
ALLO
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
Press ReleasesAllogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
3M ago
ALLO
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.